LB2. Safety and Efficacy of Combination SARS-CoV-2 Monoclonal Neutralizing Antibodies (mAb) BRII-196 and BRII-198 in Non-Hospitalized COVID-19 Patients

BACKGROUND: SARS-CoV-2 continues to spread and the development of safe and effective therapeutics for the prevention of severe disease remains a priority. BRII-196 and BRII-198 are non-competing anti-SARS-CoV-2 mAbs with YTE triple amino acid substitution in Fc to extend half-life and reduce recepto...

Descripción completa

Detalles Bibliográficos
Autores principales: Evering, Teresa H, Giganti, Mark, Chew, Kara W, Hughes, Michael, Moser, Carlee, Wohl, David Alain, Currier, Judith, Eron, Joseph J, Javan, Arzhang, Margolis, David A, Zhu, Qing, D’Andrea, Ulises, Hoover, Keila, Mocherla, Bharat R, Fletcher, Courtney, Li, Jonathan, Smith, Davey, Daar, Eric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Late Breaker Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644150/
http://dx.doi.org/10.1093/ofid/ofab466.1643

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644150/
http://dx.doi.org/10.1093/ofid/ofab466.1643

Ejemplares similares